- AMD 2018: Meet the Researchers
- An invitation to join us for Action Mesothelioma Day 2018
- JHMRF Pump Priming Grant
- JHMRF to hold scientific workshop
- JHMRF spends £450,000 on new research projects
- Oncologist researcher makes conference debut with help of JHMRF
- Lily presents to South African conference
- Radiotherapy helped one in three in largest ever trial
- Hope in mesothelioma research
- The SYSTEMS Study
- Top ten mesothelioma research priorities announced
- JHMRF funds new research projects
- COMMAND study investigates mesothelioma drug
- NIHR welcomes proposals for research into mesothelioma
- Survey launched to help identify mesothelioma treatment uncertainties
- University of Leicester leads groundbreaking mesothelioma trials
- Phase II TroVax® trial begins
- Fund awards £120,000 for chemotherapy research
- Research portfolio update
- Clinical Trials in Mesothelioma
- New clinical fellowship funded
- Research Award 2012
Tag Archives: Research
February 19, 2014
An important survey has been launched that will help to inform future research into mesothelioma diagnosis, treatments and care. The survey is now available at www.psp.nihr.ac.uk/mesothelioma/survey, and will remain open for a few months to collect data from patients, carers and clinicians.
This is part of a project being carried out by a National Institute for Health Research (NIHR)-funded ‘Priority Setting Partnership’ (PSP) recently set up by the James Lind Alliance (JLA). The survey gives patients, carers and family members affected by the disease an opportunity to identify and prioritise unanswered questions about mesothelioma. The results of the survey will be published later this year and will be used to inform the ‘top ten’ priorities for clinical research, as determined by patients, carers and clinicians.
Mesothelioma is a rare and often fatal form of cancer with very poor survival rates. It is most commonly caused by breathing in asbestos dust, but symptoms sometimes don’t show up until decades after exposure. This makes treatment difficult because the disease is often well-advanced before it is diagnosed. According to the latest government figures, in 2011 there were 2,291 deaths in Great Britain caused by mesothelioma.
Professor Dame Sally C. Davies, Chief Medical Officer and Chief Scientific Adviser at the Department of Health, said, “It is vital that we gather and listen to the views of as many people as possible so everyone knows the topics that are a priority for clinical research. Mesothelioma research has been identified as an important area and everyone needs to hear what patients, carers, families and healthcare professionals believe are the most important unanswered questions around the diagnosis, treatment and care of mesothelioma.”
Some of the ways that you can help make the project a success, are by:
- completing our survey now at www.psp.nihr.ac.uk/mesothelioma/survey
- passing on the information to encourage your family members, support networks, carers or colleagues to fill in the survey
- circulating copies of our mesothelioma postcard to relevant groups.
Ian Jarrold, Head of Research at the British Lung Foundation, said, “We are very proud to be able to support the James Lind Alliance in setting up a Priority Setting Partnership for mesothelioma, this initiative shows that the condition is now firmly on the wider health agenda. The survey, which aims to capture unanswered questions in treating mesothelioma, will provide a very clear steer to research funders regarding what research projects need to be supported in order to make advancements in the treatment of this devastating cancer.”
Set up through the JLA and funded by the NIHR, this JLA PSP is supported by The British Lung Foundation, Mesothelioma UK, The Mick Knighton Mesothelioma Research Fund, Asbestos Victims Support Groups Forum UK, The June Hancock Mesothelioma Research Fund, and Cumbria Asbestos-Related Disease Support.
Graham Sherlock-Brown, Patient Representative, said, “It is essential that research money is put into finding ways to relieve the suffering caused by this aggressive disease. Progress in treatment is long overdue and mesothelioma victims deserve far better – very few survive past five years and mesothelioma will continue to claim victims as long as asbestos is present in the UK. That’s why I’m pleased to see the launch of this important survey, which gives patients and carers a much-needed voice.”